

**ABSA**

American Biological Safety Association

1200 Allanson Road • Mundelein, IL 60060-3808 • 866-425-1385 • 847-949-1517
Fax: 847-566-4580 • E-mail: info@absa.org • Web Site: www.absa.org**President**

Karen B. Byers, MS, RBP, CBSP
Dana-Farber Cancer Institute
450 Brookline Avenue—LGM 18
Boston, MA 02215
617-632-3890
karen_byers@dfci.harvard.edu

President-Elect

LouAnn Burnett, MS, CBSP
Sandia National Laboratories
International Bio Threat Reduction
P.O. Box 5800, MS 1363
Albuquerque, NM 87185
505-284-4133
louann.burnett@gmail.com

Secretary

Betty Kupskay, MSc, RBP
University of Minnesota
W-160 Boynton Health Service
410 Church Street, SE
Minneapolis, MN 55455
612-626-5590
kupsk001@umn.edu

Treasurer

Rosamond Rutledge-Burns, MS, CBSP
National Institute of Standards & Technology
100 Bureau Drive, MS 1730
Building 301, Room B116
Gaithersburg, MD 20899-1730
301-975-5819
rburns@nist.gov

Past-President

Benjamin A. Fontes, MPH, CBSP
Yale University
Office of Environmental Health & Safety
1st Floor
135 College Street
New Haven, CT 06510
203-737-5009
benjamin.fontes@yale.edu

Councilors

Marian Downing, RBP, CBSP (13)
Michelle McKinney, CBSP (12)
Barbara Fox Nellis, RBP, CBSP (11)
Richard Rebar, RBP, CBSP (12)

2011 Biosafety Conference Chairpersons

Scientific Program Committee
Richard C. Fink, CBSP
Robert A. Heckert, DVM, PhD, CBSP
Exhibitors Advisory Committee
Stephen Sowa, MS
Local Arrangements Committee
Natasha Griffith, MS
Mimi Ton, MPH

Executive Director

Edward J. Stygar, III, MBA, CAE
ed@absaoffice.org

September 6, 2011

Office of Biotechnology Activities
National Institutes of Health
6705 Rockledge Drive, Suite 750
Bethesda, MD 20893-7985

Ladies and Gentlemen,

The American Biological Safety Association (ABSA) is an international group of biological safety professionals and is known as one of the world's foremost resources on biological safety practices. ABSA has reviewed the proposed revisions to the "NIH Guidelines for Research with Recombinant DNA (NIH Guidelines)" which were announced in the Federal Register on July 25, 2011. We have the following comments to share:

We suggest that OBA update Section II-A-3 of the NIH Guidelines with revision or insertion of information on the Risk Group assignments for the commonly used attenuated strains. Currently this section instructs readers that "Certain attenuated strains or strains that have been demonstrated to have irreversibly lost known virulence factors may qualify for a reduction of the containment level compared to the Risk Group assigned to the parent strain".

OBA should consider adding additional information to Section II-A-3 covering the assignment of Risk Group to commonly used attenuated strains. Suggested text for consideration by OBA for the proposed revision of Appendix B is as follows: "In Appendix B, some of the more commonly used attenuated strains have been assigned to a lower Risk Group classification than the parent strain." The recommended containment level for research uses of these attenuated strains is equal to the Risk Group classification with the exception that BL3 practices should be considered for high concentrations of attenuated strains of *Francisella*.

It is suggested that Appendix B be for Risk Group assignment, and if OBA would like to suggest a containment level like was done with the attenuated *Francisella* strains, then it could be done in Section II-A-3 where the risk assessment process is described and the relationship between Risk Groups and Biosafety Levels is detailed.

We appreciate this opportunity to have provided these comments regarding this proposal.

Sincerely,

Karen Byers, MS, RBP, CBSP
President
American Biological Safety Association